These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 37181817)

  • 41. A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants.
    Jiang L; Driedonks TAP; Jong WSP; Dhakal S; Bart van den Berg van Saparoea H; Sitaras I; Zhou R; Caputo C; Littlefield K; Lowman M; Chen M; Lima G; Gololobova O; Smith B; Mahairaki V; Riley Richardson M; Mulka KR; Lane AP; Klein SL; Pekosz A; Brayton C; Mankowski JL; Luirink J; Villano JS; Witwer KW
    J Extracell Vesicles; 2022 Mar; 11(3):e12192. PubMed ID: 35289114
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-β-coronavirus vaccines.
    Zhou J; Liu Z; Zhang G; Xu W; Xing L; Lu L; Wang Q; Jiang S
    J Med Virol; 2023 Jan; 95(1):e28172. PubMed ID: 36161303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.
    Oberemok VV; Laikova KV; Yurchenko KA; Marochkin NA; Fomochkina II; Kubyshkin AV
    Inflamm Res; 2020 Sep; 69(9):801-812. PubMed ID: 32656668
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
    Jia Z; Gong W
    J Korean Med Sci; 2021 May; 36(18):e124. PubMed ID: 33975397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19.
    Kackos CM; Surman SL; Jones BG; Sealy RE; Jeevan T; Davitt CJH; Pustylnikov S; Darling TL; Boon ACM; Hurwitz JL; Samsa MM; Webby RJ
    Microbiol Spectr; 2023 Feb; 11(1):e0424022. PubMed ID: 36695597
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions.
    Abulsoud AI; El-Husseiny HM; El-Husseiny AA; El-Mahdy HA; Ismail A; Elkhawaga SY; Khidr EG; Fathi D; Mady EA; Najda A; Algahtani M; Theyab A; Alsharif KF; Albrakati A; Bayram R; Abdel-Daim MM; Doghish AS
    Biomed Pharmacother; 2023 Jan; 157():113977. PubMed ID: 36370519
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
    Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
    J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines.
    Guan X; Yang Y; Du L
    Expert Rev Vaccines; 2023; 22(1):422-439. PubMed ID: 37161869
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
    Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
    Front Immunol; 2021; 12():658519. PubMed ID: 34276652
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population.
    Bednarski E; Del Rio Estrada PM; DaSilva J; Boukadida C; Zhang F; Luna-Villalobos YA; Rodríguez-Rangel X; Pitén-Isidro E; Luna-García E; Díaz Rivera D; López-Sánchez DM; Tapia-Trejo D; Soto-Nava M; Astorga-Castañeda M; Martínez-Moreno JO; Urbina-Granados GS; Jiménez-Jacinto JA; Serna Alvarado FJ; Enriquez-López YE; López-Arellano O; Reyes-Teran G; Bieniasz PD; Avila-Rios S; Hatziioannou T
    mBio; 2022 Aug; 13(4):e0084022. PubMed ID: 35735743
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Highlight of severe acute respiratory syndrome coronavirus-2 vaccine development against COVID-19 pandemic.
    Liu CH; Huang HY; Tu YF; Lai WY; Wang CL; Sun JR; Chien Y; Lin TW; Lin YY; Chien CS; Huang CH; Chen YM; Huang PI; Wang FD; Yang YP
    J Chin Med Assoc; 2021 Jan; 84(1):9-13. PubMed ID: 33186212
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preclinical study of a DNA vaccine targeting SARS-CoV-2.
    Hayashi H; Sun J; Yanagida Y; Otera T; Kubota-Koketsu R; Shioda T; Ono C; Matsuura Y; Arase H; Yoshida S; Nakamaru R; Ju N; Ide R; Tenma A; Kawabata S; Ehara T; Sakaguchi M; Tomioka H; Shimamura M; Okamoto S; Amaishi Y; Chono H; Mineno J; Komatsuno T; Saito Y; Rakugi H; Morishita R; Nakagami H
    Curr Res Transl Med; 2022 Sep; 70(4):103348. PubMed ID: 35489099
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune response.
    Oktay E; Alem F; Hernandez K; Girgis M; Green C; Mathur D; Medintz IL; Narayanan A; Veneziano R
    Commun Biol; 2023 Mar; 6(1):308. PubMed ID: 36959304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants.
    Rotondo JC; Martini F; Maritati M; Mazziotta C; Di Mauro G; Lanzillotti C; Barp N; Gallerani A; Tognon M; Contini C
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
    J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries.
    Hussain A; Rafeeq H; Asif HM; Shabbir S; Bilal M; Mulla SI; Franco M; Iqbal HMN
    Int Immunopharmacol; 2021 Oct; 99():108050. PubMed ID: 34426120
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
    Gong W; Parkkila S; Wu X; Aspatwar A
    Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nanotechnology-based strategies against SARS-CoV-2 variants.
    Huang X; Kon E; Han X; Zhang X; Kong N; Mitchell MJ; Peer D; Tao W
    Nat Nanotechnol; 2022 Oct; 17(10):1027-1037. PubMed ID: 35982317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients.
    Carreño JM; Alshammary H; Singh G; Raskin A; Amanat F; Amoako A; Gonzalez-Reiche AS; van de Guchte A; Study Group P; Srivastava K; Sordillo EM; Sather DN; van Bakel H; Krammer F; Simon V
    EBioMedicine; 2021 Nov; 73():103626. PubMed ID: 34688034
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.
    Mirzaei R; Mohammadzadeh R; Mahdavi F; Badrzadeh F; Kazemi S; Ebrahimi M; Soltani F; Kazemi S; Jeda AS; Darvishmotevalli M; Yousefimashouf R; Keyvani H; Karampoor S
    Int Immunopharmacol; 2020 Nov; 88():106928. PubMed ID: 32862110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.